United States
Research rather than routine access
Ibogaine remains illegal to possess or import in the United States. Discussions of access should therefore be separated from regulated research activity. A research claim is more useful when it can be matched to a trial registry, published protocol, and clear study oversight rather than a commercial pathway.
Canada
Legal status and care setting must be separated
Canadian access questions require careful attention to federal rules, exemptions, research pathways, and provincial clinical standards. People comparing destinations may find the country-specific context at ibogaine treatment centers in Canada useful as a starting point, while still asking for written evidence of screening, ECG review, emergency capability, credentialing, and transfer arrangements.
Mexico
Independent settings vary substantially
Mexico is frequently discussed in relation to independent ibogaine facilities, but geographic availability is not a clinical quality measure. Cost is also not a proxy for safeguards; practical comparisons should keep the cost of ibogaine treatment in Mexico separate from questions about medical supervision, emergency protocols, naloxone, and the plausibility of hospital or ICU transfer.
Europe and other regions
Confirm the current regulator position
Rules and available settings vary by jurisdiction and can change. The clearest evidence may come from a national regulator, a registered trial, or peer-reviewed safety reporting. For substance-control context across countries, the United Nations drug-control conventions provide a useful reference point, though domestic law and clinical governance still require local verification.